CORE F: SERUM ANALYTE AND BIOMARKER CORE

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 拟议的血清分析和生物标记物核心旨在满足Cobre研究人员利用高通量蛋白质组方法检测自身抗体、血清细胞因子、特异性抗体反应、血清激素水平和其他活动或人类血清或其他生物液中的生化代谢物的需求。通过科布雷临床核心中心和其他当地生物资源库的现有生物库资源，科布雷的研究人员可以获得数千份狼疮、类风湿性关节炎、干燥综合征和多发性硬化症患者的血清样本。研究人员可以使用这些样本或其他专门为他们的项目获得的样本，可以使用该核心内的资源进行基于血清的生物标记物评估。 Cobre的研究人员将能够使用基于珠的多路化验，用于高通量的人体临床样本自身抗体分析，以及使用BioRad BioPlex2200系统的其他分析，以及基于Luminex的多路细胞因子分析。为了评估抗体表位特异性和T细胞特异性，将继续提供以前的多肽核心的多肽合成服务。最后，将评估和实施新的技术和方案，以利用进行额外的蛋白质组、生物活性和生化分析的能力。 为实现这些目标，提出了以下四个目标： 目的/目标1：提供具有成本效益的途径，获得目前最先进的人类和动物血清自身抗体检测技术和方法。 目的/目标2：为Cobre研究人员在检测人类和动物样本中的细胞因子和趋化因子方面提供高级建议和意见。 目的/目标3：提供获得固相肽合成和抗体检测的技术专长和性能的途径。 目的/目标4：评估和获取新技术并开发新的血清蛋白质组、生物活性或生化分析方法，以进一步增强Cobre研究人员在临床-翻译界面进行尖端研究的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The proposed Serum Analyte & Biomarker Core is designed to meet the needs of the COBRE investigators to utilize high-throughput proteomic methods to assay autoantibodies, serum cytokines, specific antibody responses, serum hormone levels and other activities or biochemical metabolites in human serum or other biofluids. Through the existing biorepository resources in the COBRE Clinical Core and other local biorespositories COBRE investigators have access to thousands of individual's serum samples from individuals with lupus, rheumatoid arthritis, Sj¿gren's syndrome and multiple sclerosis. Investigators can use these samples or others obtained specifically for their projects can be used in serum-based evaluation of biomarkers using the resources within this Core. COBRE investigators will be provided access to the multiplex bead-based assays for high-throughput human clinical sample analysis of autoantibody and other assays using the BioRad BioPlex2200 system, as well as Luminex based multiplex cytokine assays. To assess antibody epitope specificities and T cell specificities, the peptide synthesis services of the previous Peptide Core will be continued. Finally, new technologies and protocols will be assessed and implemented to take advantage of the ability toperform additional proteomic, bioactivity and biochemical assays. To accomplish these goals, the following four aims are proposed: Aim/Goal 1: Provide cost-effective access to current state-of-the-art technologies and methods for human and animal serum autoantibody testing. Aim/Goal 2: Provide COBRE investigators with senior level advice and input to cytokine and chemokine detection in human and animal samples. Aim/Goal 3: Offer access to technical expertise and performance of solid-phase peptide syntheses and antibody testing. Aim/Goal 4: Assess and acquire new technologies and develop new methods for the analysis of serum proteomic, bioactivity or biochemical assays that can further enhance the capabilities of the COBRE researchers to do cutting-edge research at the clinical-translational interface.